Reuters logo
BRIEF-Merck discontinues MK-3682B and MK-3682C development programs
September 29, 2017 / 11:09 AM / in 19 days

BRIEF-Merck discontinues MK-3682B and MK-3682C development programs

Sept 29 (Reuters) - Merck & Co Inc:

* Merck discontinues MK-3682B and MK-3682C development programs

* Merck & Co Inc - company to focus on maximizing potential of Zepatier (Elbasvir and Grazoprevir)

* Merck - ‍decision made based on review of phase 2 efficacy data, considering of evolving marketplace, growing treatment options Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below